Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Cboe UK • CHF Idorsia Ltd (IDIAZ.XC) Follow Add holdings 1.4780 +0.1920 +(14.93%) At close: May 2 at 4:16:39 PM GMT+1 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for IDIAZ.XC 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: IDIAZ.XC View More All News Press Releases SEC Filings Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement Idorsia publishes its Annual Report 2024 US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia Idorsia Ltd (IDRSF) (Q4 2024) Earnings Call Highlights: Strategic Moves and Financial Resilience Idorsia announces financial results for 2024